EvoGenix clears second hurdle in GSK pact

EvoGenix is touting the launch of its second project with GlaxoSmithKline as clear validation of its drug development know-how. The Australian biotech is helping Glaxo develop antibodies. "EvoGenix is employing its protein engineering technologies in developing a series of protein therapeutics with a particular focus on antibody-based drugs," the company said. EvoGenix earns research funds and new milestones as it progresses in its deal to collaborate on up to three different projects.

- check out the release
- here's the report from The Age

Related Article:
Peptech buys EvoGenix in $156M antibody deal. Report
New study highlights risks of anti-TNF antibody class. Report

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.